Evaluating an In-House Cell-Based Assay for Detecting Antibodies Against Muscle-Specific Tyrosine Kinase in Myasthenia Gravis
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Detecting antibodies against muscle-specific tyrosine kinase (MuSK Abs) is essential for diagnosing myasthenia gravis (MG). We applied an in-house cellbased assay (CBA) to detect MuSK Abs. Methods A stable cell line was generated using a lentiviral vector, which allowed the expression of MuSK tagged with green fluorescent protein in human embryonic kidney 293 (HEK293) cells. Serum and anti-human IgG antibody conjugated with red fluorescence were added. The presence of MuSK Abs was determined based on the fluorescence intensity and their colocalization in fluorescence microscopy. Totals of 218 serum samples collected from 177 patients with MG, 31 with other neuromuscular diseases, and 10 healthy controls were analyzed. The CBA results were compared with those of a radioimmunoprecipitation assay (RIPA) and an enzyme-linked immunosorbent assay (ELISA). Results The MuSK-HEK293 cell line stably expressed MuSK protein. The CBA detected MuSK Abs in 34 (19.2%) of 177 samples obtained from patients with MG and in none of the participants having other neuromuscular diseases or in the healthy controls. The clinical characteristics of the patients with MuSK MG determined based on the CBA were strongly correlated with known clinical features of MuSK MG. There was an almost perfect agreement between the results of the CBA and those of the RIPA (Cohen’s kappa=0.880, p<0.001) and ELISA (Cohen’s kappa=0.982, p<0.001). Conclusions The results of the in-house CBA showed excellent agreement with both the RIPA and ELISA. Our in-house CBA can be considered a reliable method for detecting MuSK Abs.
Abstract
Background and Purpose Detecting antibodies against muscle-specific tyrosine kinase (MuSK Abs) is essential for diagnosing myasthenia gravis (MG). We applied an in-house cellbased assay (CBA) to detect MuSK Abs. Methods A stable cell line was generated using a lentiviral vector, which allowed the expression of MuSK tagged with green fluorescent protein in human embryonic kidney 293 (HEK293) cells. Serum and anti-human IgG antibody conjugated with red fluorescence were added. The presence of MuSK Abs was determined based on the fluorescence intensity and their colocalization in fluorescence microscopy. Totals of 218 serum samples collected from 177 patients with MG, 31 with other neuromuscular diseases, and 10 healthy controls were analyzed. The CBA results were compared with those of a radioimmunoprecipitation assay (RIPA) and an enzyme-linked immunosorbent assay (ELISA). Results The MuSK-HEK293 cell line stably expressed MuSK protein. The CBA detected MuSK Abs in 34 (19.2%) of 177 samples obtained from patients with MG and in none of the participants having other neuromuscular diseases or in the healthy controls. The clinical characteristics of the patients with MuSK MG determined based on the CBA were strongly correlated with known clinical features of MuSK MG. There was an almost perfect agreement between the results of the CBA and those of the RIPA (Cohen’s kappa=0.880, p<0.001) and ELISA (Cohen’s kappa=0.982, p<0.001). Conclusions The results of the in-house CBA showed excellent agreement with both the RIPA and ELISA. Our in-house CBA can be considered a reliable method for detecting MuSK Abs.
참고문헌 (29)
- Evoli A, "Response to therapy in myasthenia gravis with anti-MuSK antibodies", Ann N Y Acad Sci, 1132, pp.76~83 (2008)
- Deymeer F, "Clinical comparison of anti-MuSK-vs anti-AChR-positive and seronegative myasthenia gravis", Neurology, 68, pp.609~611 (2007)
- Farrugia ME, "MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis", Brain, 129(Pt 6), pp.1481~1492 (2006)
- 김승우, "Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis", Journal of Clinical Neurology, 13(3), pp.287~292 (2017), 대한신경과학회[DOI]
- Oh SJ, "Different characteristic phenotypes according to antibody in myasthenia gravis", J Clin Neuromuscul Dis, 14, pp.57~65 (2012)
- Guptill JT, "Anti-MuSK antibody myasthenia gravis : clinical findings and response to treatment in two large cohorts", Muscle Nerve, 44, pp.36~40 (2011)
- Stickler DE, "MuSK-antibody positive myasthenia gravis : clinical and electrodiagnostic patterns", Clin Neurophysiol, 116, pp.2065~2068 (2005)
- Devic P, "Antibodies to clustered acetylcholine receptor : expanding the phenotype", Eur J Neurol, 21, pp.130~134 (2014)
- Leite MI, "IgG1antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis", Brain, 131(Pt 7), pp.1940~1952 (2008)
- Park KH, "Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea : autoantibody profiles and clinical features", PLoS One, 13, pp.e0193723~ (2018)
- Tsonis AI, "MuSK autoantibodies in myasthenia gravis detected by cell based assay--a multinational study", J Neuroimmunol, 284, pp.10~17 (2015)
- Brooks BR, "El Escorial revisited : revised criteria for the diagnosis of amyotrophic lateral sclerosis", Amyotroph Lateral Scler Other Motor Neuron Disord, 1, pp.293~299 (2000)
- Van den Bergh PY, "European Federation of Neurological Societies", Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision, 2010, pp.17, 356~363
- Titulaer MJ, "Lambert-Eaton myasthenic syndrome : from clinical characteristics to therapeutic strategies", Lancet Neurol, 10, pp.1098~1107 (2011)
- Bohan A, "Polymyositis and dermatomyositis(first of two parts)", N Engl J Med, 292, pp.344~347 (1975)
- Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, "Myasthenia gravis : recommendations for clinical research standards", Neurology, 55, pp.16~23 (2000)
- 강은숙, "Clinical Usefulness of Cell-based Indirect Immunofluorescence Assay for the Detection of Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder", Annals of Laboratory Medicine, 32(5), pp.331~338 (2012), 대한진단검사의학회
- Huda S, "IgG-specific cell-based assay detects potentially pathogenic MuSKAbs in seronegative MG", Neurol Neuroimmunol Neuroinflamm, 4, pp.e357~ (2017)
- Chang T, "Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population", J Neurol Sci, 343, pp.82~87 (2014)
- Yang L, "Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China", J Neurol Sci, 301, pp.71~76 (2011)
- Takata K, "Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients", JCI Insight, 4, pp.e127167~ (2019)
- McConville J, "Detection and characterization of MuSK antibodies in seronegative myasthenia gravis", Ann Neurol, 55, pp.580~584 (2004)
- Tandon N, "Generation of stable expression mammalian cell lines using lentivirus", Bio Protoc, 8, pp.e3073~ (2018)
- Triplett JD, "Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients : a marker of relapse?", Muscle Nerve, 60, pp.307~311 (2019)
- Hain B, "Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab", Muscle Nerve, 33, pp.575~580 (2006)
- Díaz-Manera J, "Long-lasting treatment effect of rituximab in MuSK myasthenia", Neurology, 78, pp.189~193 (2012)
- Sanders DB, "Clinical aspects of MuSK antibody positive seronegative MG", Neurology, 60, pp.1978~1980 (2003)
- Farrugia ME, "Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies", Clin Neurophysiol, 118, pp.269~277 (2007)
- Wolfe GI, "Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis", Ann N Y Acad Sci, 1132, pp.71~75 (2008)